AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
Prior Approval Supplement (PAS) for VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® assigned a Prescription Drug User Fee Act (PDUFA)...
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr....
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the...
- Company to host conference call and webcast on Thursday, August 24that 8:30 am EDT - LYON, France, August 10,...
NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
- Patient enrollment has commenced in landmark pivotal trial for lead product...
Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): XACIATO™ First Commercial SaleOvaprene®...
Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational...
– Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company –...
Researchers Call for Larger Clinical Trial Citing Outcomes from Study Oak Ridge, TN, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Daxor...
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call...
POMPANO BEACH, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to freeing patients from...
$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to Support Operations into the Second...
ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- The Georgia Health Information Network (GaHIN), Georgia’s state-designated health information exchange (HIE), has...
Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical...
Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure 3 Clearing in a lawn...
Tigris Trial Enrollment Reaches 71 PatientsTORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:...
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...
Strong Sales of $5.5 million alongside Drug Partnering AgreementMISSISSAUGA, Ontario, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX:...